AP

Arvind Parmar

The University of Sydney, Australian Nuclear Science and Technology Organisation, Maharaja Sayajirao University of Baroda, AstraZeneca (United Kingdom)

ORCID iD 0009-0000-6615-6583
Follow

About

Dr. Arvind Parmar is an esteemed Imaging Scientist and Pharmacologist with an illustrious career spanning over two decades. His passion for advancing scientific knowledge is reflected in his groundbreaking Preclinical PET Imaging project, where he applies cutting-edge methodologies and innovative research approaches to propel the field forward.

Throughout his distinguished career, Dr. Parmar has demonstrated exceptional leadership acumen. His proficiency in managing preclinical imaging facilities, leading multidisciplinary teams, and spearheading research projects in prestigious institutions globally showcases his commitment to pushing the boundaries of scientific exploration. His track record is marked by high-impact publications, successful collaborations, and the acquisition of substantial research grants.

Dr. Parmar's primary expertise lies in Pharmacodynamics & Pharmacokinetics (PK/PD) studies utilising preclinical imaging techniques. He excels in designing, executing, and analysing studies that unravel the complexities of drug behaviour and efficacy in vivo. His specialisation in Preclinical Molecular Imaging involves employing molecular techniques to visualise and quantify biological processes, significantly contributing to drug development and validation.

A notable strength of Dr. Parmar is his ability to bridge the gap between preclinical findings and clinical applications through Clinical Translational Research. This ensures the seamless translation of research insights into actionable clinical outcomes, showcasing his holistic understanding of the drug development process.

Leadership excellence is a hallmark of Dr. Parmar's career, evident in his adept management of multidisciplinary teams and state-of-the-art facilities. He fosters collaboration, innovation, and operational excellence, and his proficiency in Collaborative Research is noteworthy, collaborating seamlessly with experts in in vitro biology, protein engineering, and PK sciences to advance programs toward clinical development.

Dr. Parmar is widely recognised for his expertise in In Vivo Study Design & Execution, particularly in inflammatory and neuroscience-based disease models. This proficiency ensures the generation of robust data, contributing significantly to the advancement of our understanding of various diseases.

His unique skill set extends to the application of advanced tools and methodologies for comprehensive in vivo and ex vivo assessment of therapeutic mechanisms of action, with a specific focus on antibody therapeutics. This includes the development of supporting assays to evaluate target modulation and downstream effects at cellular, protein, and genetic levels, ensuring a holistic understanding of drug mechanisms.

Exemplifying strategic thinking, Dr. Parmar formulates nonclinical pharmacology strategies and generates comprehensive documentation to support clinical trials, publications, and external communications. His ability to address complex challenges, analyze intricate data sets, and communicate insights effectively significantly contributes to data-driven decision-making processes.

Dr. Parmar is dedicated to staying at the forefront of the field by continually evaluating emerging technologies and innovative models. This commitment ensures the incorporation of cutting-edge approaches in drug discovery and development, enhancing predictive accuracy for human diseases.

In summary, Dr. Arvind Parmar is an accomplished PET Imaging Scientist and Pharmacologist with a proven track record in preclinical imaging, in vivo pharmacology, and translational research. His leadership, expertise, and unwavering commitment to advancing scientific knowledge make him an ideal candidate for support in his groundbreaking Preclinical PET Imaging project.

Employment

  • The University of Sydney Technical and Facility Manager
    2022 - Present
  • Australian Nuclear Science and Technology Organisation Imaging scientist and Manager(acting) Preclinical Imaging and Biology Group
    2011 - 2022
  • AstraZeneca (United Kingdom) Imaging Scientist
    2008 - 2010
  • University of Manchester Postdoctoral Research Scientist
    2006 - 2008

Education

  • Maharaja Sayajirao University of Baroda PhD in Pharmacology
    2003 - 2008
  • Maharaja Sayajirao University of Baroda Masters in Pharmacology
    1999 - 2001

Projects & Funding

Projects & funding information is unavailable.

Publications (23)